

## A Carelon Company

#### **PATIENT INFORMATION:**

# P: 877.365.5566 | F: 855.889.2946

NEUROLOGY

**ORDER SET** 

Patient Name:

Fax completed form, insurance information, and clinical documentation to 855.889.2946

DOB: Phone:

**Patient Status:** □ New to Therapy □ Continuing Therapy

#### **MEDICAL INFORMATION**

Patient Weight: \_\_\_\_\_ lbs. (required) Allergies: \_

#### Lab orders: \_

\_ **Frequency**: 🗆 Each infusion 🛛 Other: \_\_\_\_\_

**Next Treatment Date:** 

Required labs to be drawn by: □ Paragon □ Referring provider

Diagnosis	Infusion Orders			
□ Pompe Disease ICD-10:	Lumizyme 20mg/kg IV every 2 weeks x1 year Nexviazyme 20mg/kg IV every 2 weeks x1 year			
□ Migraines ICD-10:	Vyepti: 🗆 100mg IV every 3	months x1 year OR	□ 300mg IV every 3 months x1 year	
□ MS □ Other: ICD-10:	Solu-Medrol 1gm IV daily	xday(s)	OR □ Solu-Cortef 1gm IV daily x day(s)	
Diagnosis: ICD-10:	Soliris:       900mg IV weekly for the first 4 weeks, followed by 1200mg for the fifth dose 1 week later, then 1200mg every 2 weeks thereafter x1 year (initial start with maintenance)         1200mg IV every 2 weeks x1 year (maintenance dosing)			
Multiple Sclerosis  ICD-10:	<ul> <li>□ Ocrevus* □ 300mg IV at 0 □ 600mg IV even</li> <li>□ Ocrevus Zunovo 920mg/23 Premed protocol: dexame</li> <li>□ Briumvi* □ 150mg IV x1, th □ 450mg IV even</li> </ul>	and 2 weeks, then 6 y 6 months x1 year 3,000units subcutan ethasone 20mg PO & en 450mg IV 2 wee y 24 weeks x1 year	er registering patient with TOUCH) 500mg IV every 6 months x1 year eously every 6 months x1 year cetirizine 10mg PO 30 minutes prior to Ocrevus Zunova ks later, followed by 450mg IV every 24 weeks x1 year dryl 25mg PO/IV to be given 30 minutes before infusion	
🗆 Diagnosis:	IVIg Orders:	mg/kg OR	gm/kg IV divided over day(s) g one time dose only	
ICD-10:	Preferred brand:	weeks x1 year <b>OF</b> (Parago	I contained to the contract of the contract	
	(neuro dosing)	IV followed 2 wee dose of: □ 3,000m	9kg) □ 2,700mg (60-99kg) □ 3,000mg (100kg+) ks later by g (40-59kg) □ 3,300mg (60-99kg) g IV (100kg+) IV every 8 weeks x1 year	
□ Diagnosis: Myasthenia Gravis ICD-10:	□ 1200mg IV c *Cycle may be repeated Vyvgart Hytrulo: □ 1,008 m	>50 days from start of pr g / 11,200 units suk	ekly for 4 weeks (≥120kg) evious cycle. Subsequent cycles may be ordered as appropriate	
Diagnosis: CIDP (Vyvgart Hytrulo)		• •	revious cycle. Subsequent cycles may be ordered as appropriate	
ICD-10:			0kg: 560mg □ ≥100kg: 840mg subQ weekly x6 revious cycle. Subsequent cycles may be ordered as appropriate	
	wee	eks thereafter x 1 ye	mg/kg IV 2 weeks later, then 15mg/kg IV every 2 ear ery 2 weeks x 1 year	
hATTR amyloidosis ICD-10:	□ Amvuttra 25mg SubQ eve	ery 3 months x1 yea	r	
Pre-medication Orders			Benadryl 25mg PO □ Benadryl 25mg IV Solu-Medrol mg IVP □ Other:	
PROVIDER INFORMATI	ON			
agent in dealing with medical and prescription i	nsurance companies, and to select the p	preferred site of care for t		
Provider Name:	Sign Phone <sup>.</sup>	ature:	Date: Contact Person:	

Provider NPI: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_ Contact Person: \_ □ Opt out of Paragon selecting site of care (if checked, please list site of care):

#### **PREFERRED LOCATION**

$\sim$	• •		
(	ıt.	۱/	•
$\sim$	ιu		

State:

View our locations here:



PARAGONHEALTHCARE.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.





## COMPREHENSIVE SUPPORT FOR NEUROLOGY THERAPY

A Carelon Company

### PATIENT INFORMATION:

Patient Name:	DOB:
REQUIRED DOCUMENTATION FOR REFERRAL P	ROCESSING & INSURANCE APPROVAL
Include signed and completed order (MD/prese	criber to complete page 1)
Include patient demographic information and i	nsurance information
Include patient's medication list	
□ Supporting clinical notes (H&P) to support prir	nary diagnosis
Has the patient tried and failed previous drug	therapy?
If yes, which drug(s)?	
Labs attached	
☐ JCV antibody (Tysabri orders)	
AChR antibody or MuSK antibody (Rystiggo	, Imaavy, Vyvgart & Ultomiris)
Hepatitis B antigen and Hepatitis B core tota	Il antibody (Ocrevus & Briumvi)
🗌 Serum immunoglobulins (Ocrevus & Briumvi	)
Other supporting labs based on diagnosis/o	rder
Diagnostic testing	
MRI documentation (Tysabri, Ocrevus, Brium	nvi)
□ Other diagnostic testing to support diagnos	is/order
Vaccine record	
Meningococcal vaccinations - both Men B and a second se	nd Men ACWY (Soliris & Ultomiris orders)
Other medical necessity:	

Paragon Healthcare will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

## Please fax all information to (855) 889-2946 or call (877) 365-5566 for assistance

PARAGONHEALTHCARE.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.